ACOR - Acorda partners with Biopas to sell Parkinson's disease therapy in Latin America

The commercial-stage biotech, Acorda Therapeutics (NASDAQ:ACOR), and South American pharma company, Biopas Laboratories announced an agreement on Wednesday to commercialize Acorda’s (ACOR) Parkinson's disease therapy Inbrija in certain Latin American countries. Accordingly, Biopas will be entitled to exclusive distribution rights to the treatment in countries such as Brazil and Mexico. Per the terms of the agreement, Acorda (ACOR) is set to receive a double-digit tiered percentage of the selling price in the region and sales-based milestones for the delivery of Inbrija to Biopas. “We are also in active discussions with other companies for the rights to commercialize INBRIJA in additional countries,” Acorda (ACOR) Chief Executive Ron Cohen said. Inbrija is approved in the U.S. for intermittent treatment of episodic motor fluctuations in adults with Parkinson's disease who have received a levodopa/dopa-decarboxylase inhibitor. In 2021, Acorda (ACOR) reported $29.6 million of net revenue from Inbrija indicating ~22% YoY growth.

For further details see:

Acorda partners with Biopas to sell Parkinson's disease therapy in Latin America